Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
| Authors | Onima Chowdhury, Jennifer O'Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa K Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben Mesa, Francesco Passamonti, Vincent Ribrag, Gary Schiller, Alessandro M Vannucchi, Daobin Zhou, Mary Frances McMullin, Jianhua Zhong, Robert Peter Gale, Adam J Mead, RESUME trialists |
| Journal | Leukemia
(Leukemia)
Vol. 35
Issue 4
Pg. 1197-1202
(04 2021)
ISSN: 1476-5551 [Electronic] England |
| PMID | 32770086
(Publication Type: Letter, Research Support, Non-U.S. Gov't)
|
| Chemical References |
|
| Topics |
- Disease Management
- Disease Susceptibility
- Erythrocyte Transfusion
(adverse effects, methods)
- Humans
- Mutation
- Myeloproliferative Disorders
(complications, genetics)
- Primary Myelofibrosis
(diagnosis, etiology, therapy)
- Spliceosomes
(genetics)
- Thalidomide
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
